Literature DB >> 15074313

Endoscopic and surgical palliation of gastrointestinal tumors.

M Hünerbein1.   

Abstract

Approximately 40-50% of patients with gastrointestinal tumors are not candidates for curative surgery because of locally advanced tumors or metastatic disease. In the course of the disease most of these patients will require palliative treatment because of obstruction, fistula, pain or hemorrhage. Various endoscopic and surgical procedures can be offered to these patients to alleviate the symptoms of the disease, to improve quality of life and to increase their survival time. However, the potential risk of each treatment must be balanced carefully with the expected benefits and the prognosis of the individual patient. Consequently, minimally invasive procedures, i.e. endoscopic and laparoscopic procedures, have been increasingly used for palliation in recent years. This article provides an overview on endoscopic and surgical palliation of gastrointestinal tumors on the basis of our own experience and a review of the literature.

Entities:  

Mesh:

Year:  2004        PMID: 15074313     DOI: 10.1007/s00520-003-0514-0

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  33 in total

Review 1.  Endoscopic palliation of malignant dysphagia.

Authors:  D G Adler; T H Baron
Journal:  Mayo Clin Proc       Date:  2001-07       Impact factor: 7.616

2.  Palliation of inoperable esophageal carcinoma: a prospective randomized trial of laser therapy and stent placement.

Authors:  A Adam; J Ellul; A F Watkinson; B S Tan; R A Morgan; M P Saunders; R C Mason
Journal:  Radiology       Date:  1997-02       Impact factor: 11.105

Review 3.  Palliative treatment of malignant esophagorespiratory fistulas with Gianturco-Z stents. A prospective clinical trial and review of the literature on covered metal stents.

Authors:  A May; C Ell
Journal:  Am J Gastroenterol       Date:  1998-04       Impact factor: 10.864

Review 4.  Esophageal cancer: a systematic review.

Authors:  R Wong; R Malthaner
Journal:  Curr Probl Cancer       Date:  2000 Nov-Dec       Impact factor: 3.187

5.  Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice.

Authors:  J R Andersen; S M Sørensen; A Kruse; M Rokkjaer; P Matzen
Journal:  Gut       Date:  1989-08       Impact factor: 23.059

6.  Expandable metal stents versus laser combined with radiotherapy for palliation of unresectable esophageal cancer: a prospective randomized trial.

Authors:  A Königsrainer; B Riedmann; A De Vries; D Ofner; B Spechtenhauser; F Aigner; E Fritsch; R Margreiter
Journal:  Hepatogastroenterology       Date:  2000 May-Jun

7.  Comparison between endoscopic laser and different surgical treatments for palliation of advanced rectal cancer.

Authors:  W Tacke; S Paech; W Kruis; H Stuetzer; J M Mueller; D J Ziegenhagen; E Zehnter
Journal:  Dis Colon Rectum       Date:  1993-04       Impact factor: 4.585

8.  Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction.

Authors:  P H Davids; A K Groen; E A Rauws; G N Tytgat; K Huibregtse
Journal:  Lancet       Date:  1992 Dec 19-26       Impact factor: 79.321

9.  [Risk of surgical therapy of stomach cancer in Germany. Results of the German 1992 Stomach Cancer Study. German Stomach Cancer Study Group ('92)].

Authors:  K Böttcher; J R Siewert; J D Roder; R Busch; P Hermanek; H J Meyer
Journal:  Chirurg       Date:  1994-04       Impact factor: 0.955

10.  The role of staging laparoscopy for multimodal therapy of gastrointestinal cancer.

Authors:  M Hünerbein; B Rau; P Hohenberger; P M Schlag
Journal:  Surg Endosc       Date:  1998-07       Impact factor: 4.584

View more
  1 in total

1.  Venting direct percutaneous jejunostomy (DPEJ) for drainage of malignant bowel obstruction in patients operated on for gastric cancer.

Authors:  Giuseppe Piccinni; Anna Angrisano; Mario Testini; Domenico Merlicco; Michele Nacchiero
Journal:  Support Care Cancer       Date:  2005-02-15       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.